Johnson & Johnson announced on Friday that a single infusion of its CARVYKTI cancer therapy kept half of a small group of patients with early-line relapsed or refractory multiple myeloma alive and...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.